三生制药(01530)再涨超6%,截至发稿,涨4.7%,报21.15港元,成交额5.46亿港元。消息面上,5月20日,三生制药宣布将其自主研发的PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的独家开发、生产、商业化权利授予全球药企巨头辉瑞,总交易金额最高可达60.5亿美元,以及根据授权地区产品销售额计算得到的两位数百分比的梯度销售分成,辉瑞同时1亿美元战略入股。华西证券指出...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.